IHC (n) | Age range (median) | IHC loss | % IHC loss | Path_MMR with loss | % | |
Colorectal cancer | 2204 | 14.5–91 (50.8) | 422 | 19.15 | 155 | 7.03 |
Colorectal polyps | 244 | 8.4–82 (54) | 8 | 3.28 | 3 | 1.23 |
Endometrial cancer | 739 | 183 | 24.76 | 44 | 5.95 | |
Genetics service | 239 | 16–79 (51) | 28 | 11.7 | ||
PETALS | 500 | (65) | 16 | 3.2 | ||
Gastric cancer | 58 | 17–79 (48) | 5 | 8.62 | 0 | 0.00 |
Ovarian cancer | 261 | 16–89 (49) | 27 | 10.34 | 8 | 3.07 |
TCC/kidney | 13 | 32–61 (45) | 3 | 23.08 | 1 | 7.69 |
Non-melanoma skin cancer | 29 | 37–75 (57) | 12 | 41.38 | 3 | 10.34 |
Cholangiocarcinoma | 20 | 32–76 (50) | 5 | 25.00 | 0 | 0.00 |
Pancreas | 13 | 37–71 (53) | 1 | 7.69 | 0 | 0.00 |
Brain | 12 | 9–84 (48) | 4 | 33.33 | 1 | 8.33 |
Breast | 15 | 33–74 (49) | 0 | 0.00 | 0 | 0.00 |
Small bowel including ampulla | 21 | 29–72 (48) | 1 | 4.76 | 0 | 0.00 |
Unknown primary | 19 | 26–71 (40) | 0 | 0.00 | 0 | 0.00 |
Oesophagus | 16 | 21–61 (51) | 1 | 6.25 | 0 | 0.00 |
Other | 30 | 0 | 0.00 | 0 | 0.00 | |
Total | 3694 | 672 | 215 |
TCC urinary tract; others include cervix (n=4), prostate (n=4), sarcoma (n=3), melanoma (n=3), thyroid (n=2) and lung (n=2).
IHC, immunohistochemistry; MMR, mismatch repair; path_, pathogenic variant; PETALS, Proportion of Endometrial Tumours Associated with Lynch Syndrome; TCC, transitional cell carcinoma.